{"entity":{"id":"azd6621","kind":"drug","name":"AZD6621","aka":[],"tldr":"AZD6621 is an experimental T-cell engager from AstraZeneca in phase 2 trials for prostate cancer, aimed at CD3.","summary":"AZD6621 is a T-cell engager developed by AstraZeneca. Its target is CD3 (the sponsor names STEAP2 x CD3 x CD8). The sponsor states: AZD6621 is a T-cell-engaging antibody that targets STEAP2, CD3 and CD8, designed to engage T cells against STEAP2-expressing prostate cancer cells (ACTIVATED-4-PC study). ClinicalTrials.gov describes the intervention as: A T Cell-engaging Antibody that targets STEAP2, CD3, and CD8. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in prostate cancer. The largest, NCT07192614, plans to enrol 52 participants with primary completion expected 2029-03-29. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of AZD6621","url":"https://clinicaltrials.gov/search?intr=AZD6621"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":["cd3"],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07192614"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"T-cell engager","mechanism":"AZD6621 is a T-cell-engaging antibody that targets STEAP2, CD3 and CD8, designed to engage T cells against STEAP2-expressing prostate cancer cells (ACTIVATED-4-PC study).","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/azd6621/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"trial":[{"id":"nct07192614","kind":"trial","name":"A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Pr","route":"/trials/nct07192614/"}]}}